Praluent Cost in Oregon 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Praluent Actually Cost in Oregon in 2026?

The manufacturer list price for Praluent is approximately $580 per month in 2026, which reflects twice-monthly subcutaneous injections of either the 75 mg or 150 mg prefilled pen. That figure is the starting point, not the endpoint, for most Oregon patients. Insurance coverage, manufacturer assistance programs, and compounding options can each change what you actually pay at the pharmacy counter.

Regeneron and Sanofi set the wholesale acquisition cost (WAC) at around $580 per 28-day supply regardless of dose strength. Oregon retail pharmacies generally pass that list price to uninsured or underinsured cash-pay patients with minimal markup. GoodRx and similar discount platforms occasionally show prices between $530 and $580 at Oregon chains such as Fred Meyer, Walgreens, and Rite Aid, though these prices shift month to month and do not apply if you also use insurance.

Alirocumab works by binding proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. By blocking PCSK9, the drug increases the number of LDL receptors available to clear LDL-C from circulation. The FDA approved alirocumab in July 2015 based on the ODYSSEY LONG TERM trial, which showed a 61% reduction in LDL-C from baseline at 24 weeks in patients with heterozygous familial hypercholesterolemia (HeFH) or high cardiovascular risk already on maximum-tolerated statin therapy. [1]

The ODYSSEY OUTCOMES trial (N=18,924) subsequently demonstrated a 15% relative risk reduction in the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, compared with placebo, in patients who had experienced acute coronary syndrome within 1 to 12 months prior to enrollment. [2] The absolute risk reduction over a median follow-up of 2.8 years was 1.6 percentage points (P<0.001). That trial is the primary reason most cardiovascular guidelines now recommend PCSK9 inhibitors for post-ACS patients who remain above LDL-C targets despite maximally tolerated statin and ezetimibe therapy. [3]

Does Oregon Medicaid (OHP) Cover Praluent?

Oregon Health Plan covers alirocumab with prior authorization for members who meet specific clinical criteria. Coverage is not automatic, and denials for missing documentation are the most common access barrier.

Oregon's fee-for-service Medicaid drug program follows the Oregon Health Authority Pharmacy and Therapeutics (P&T) Committee recommendations. As of 2026, Praluent is covered for two primary diagnoses: heterozygous familial hypercholesterolemia confirmed by genetic testing or clinical criteria (Dutch Lipid Clinic Network score 6 or higher), and established atherosclerotic cardiovascular disease (ASCVD) where LDL-C remains above 70 mg/dL despite at least 90 days of maximum-tolerated statin therapy plus ezetimibe. [4]

The prior authorization process typically requires documentation of a qualifying LDL-C value from within the past 12 months, evidence of statin and ezetimibe use or a documented intolerance, and a prescribing cardiologist or endocrinologist note confirming the clinical indication. Processing time runs 3 to 15 business days depending on the coordinated care organization (CCO). Expedited reviews are available when a prescriber documents urgent clinical need.

Oregon Medicaid managed care members enrolled through a CCO may face additional formulary restrictions at the CCO level, even if the state fee-for-service program covers the drug. Patients should confirm coverage directly with their CCO before the prescription is submitted to the pharmacy. The American College of Cardiology's 2022 PCSK9 inhibitor access guidance notes that "prior authorization criteria for PCSK9 inhibitors vary substantially across state Medicaid programs and represent a significant barrier to guideline-recommended therapy." [5]

For patients whose initial PA request is denied, the Oregon Health Authority appeals process allows a standard appeal within 90 days of the denial notice and an expedited appeal within 72 hours for clinically urgent situations. [6]

How Do Commercial Insurance Plans in Oregon Handle Praluent?

Most commercial plans sold in Oregon cover Praluent on Tier 4 or Tier 5 specialty formulary tiers, which means cost-sharing runs from $150 to $400 per month before out-of-pocket maximums kick in.

Oregon's largest commercial insurers, including PacificSource, Moda Health, Providence Health Plan, and Kaiser Permanente Northwest, each maintain their own formulary for Praluent. Kaiser, for example, prefers evolocumab (Repatha) on its specialty formulary in some plan designs and requires step therapy through evolocumab before authorizing alirocumab. PacificSource commercial plans require prior authorization with documentation of a baseline LDL-C above 70 mg/dL and failure of at least two maximally tolerated statins. [7]

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states that "in patients with LDL-C levels persistently above 70 mg/dL (1.8 mmol/L) while receiving maximally tolerated statin therapy and ezetimibe, it is reasonable to add a PCSK9 inhibitor." [8] That language gives prescribers a clinical basis to push back on insurer denials that claim insufficient medical necessity.

Step therapy requirements are common. Oregon law (ORS 743B.013) allows patients to request an exception to step therapy protocols when the required prior drug is medically inappropriate or has already been tried and failed. [9] Prescribers can invoke this statute to bypass an evolocumab-first requirement when there is a documented clinical reason to start with alirocumab specifically.

Out-of-pocket maximums under ACA-compliant Oregon plans in 2026 are $9,450 for an individual and $18,900 for a family. Specialty drug costs accumulate toward these caps, so patients who pay $300 per month in the first several months of the year may reach their cap and pay nothing for the remainder of the plan year.

How Does the Regeneron and Sanofi Praluent Savings Card Work in Oregon?

The Praluent Co-pay Card reduces monthly costs to $0 for commercially insured patients who meet income and eligibility requirements. The card does not apply to government-funded insurance, including OHP, Medicare Part D, or TRICARE.

Regeneron and Sanofi jointly administer the Praluent MyWay savings program. Commercially insured patients in Oregon can enroll online or through their prescriber's office. The card covers the gap between the plan's copay and the drug's cost, up to a defined annual maximum (currently $13,000 per calendar year per patient). [10] That ceiling is high enough that the vast majority of commercially insured Oregon patients pay $0 per month.

Eligibility requires that the patient is not enrolled in any federal or state government health insurance program. Part D patients are excluded. Patients with OHP secondary insurance are also excluded because OHP is a state Medicaid program. Income verification is not required for the standard co-pay card, though a separate patient assistance program (Praluent MySupport) offers free drug to uninsured or underinsured patients whose household income falls below 600% of the federal poverty level. [10]

Oregon patients who lose commercial insurance mid-year, such as after a job change, should notify the program immediately. Coverage under the savings card terminates when commercial insurance lapses, and the patient would then need to reapply under whichever new coverage they obtain.

Is Compounded Alirocumab Legal in Oregon?

Compounded alirocumab is legally available in Oregon through licensed 503A compounding pharmacies when a physician writes a patient-specific prescription. This is not a gray area under current Oregon Board of Pharmacy regulations.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients based on a valid prescription when the compounded product is not commercially available in the needed form or when a patient has a documented clinical need the commercial product cannot meet. [11] Alirocumab is commercially available, so the prescriber must document a specific reason. Common documented reasons include intolerance to an excipient in the commercial pen, need for a dose not available commercially, or cost-related access failure when commercial and government coverage options have been exhausted.

Oregon Board of Pharmacy licenses 503A compounding pharmacies under ORS Chapter 689. Compounded alirocumab from a licensed Oregon 503A pharmacy is legally distinct from mass-produced compounded drugs distributed across state lines, which would require 503B outsourcing facility status. The active pharmaceutical ingredient (API) used in compounding must meet United States Pharmacopeia (USP) standards, and the compounding pharmacy must source API from an FDA-registered supplier. [12]

Cost is the primary draw. Compounded alirocumab from a licensed 503A pharmacy in Oregon is priced at significantly lower rates than the Regeneron/Sanofi commercial product, with some pharmacies quoting monthly costs well below the $580 commercial list price. Patients without commercial insurance and who do not qualify for OHP represent the population most likely to benefit from this pathway.

Physicians should be aware that compounded biologics carry quality and sterility considerations distinct from small-molecule compounds. Alirocumab is a monoclonal antibody, and confirming the compounding pharmacy's track record, testing protocols, and beyond-use dating practices is appropriate before prescribing. The FDA has noted that compounded versions of biologic drugs "may not be required to demonstrate the same safety, effectiveness, and quality as FDA-approved drugs." [12]

The HealthRX clinical team uses the following four-step access framework for Oregon patients who need alirocumab but face a cost barrier:

1. Confirm commercial insurance status. If the patient has active commercial coverage, enroll in the Praluent MyWay co-pay card first, as this pathway reaches $0/month cost fastest.
2. If the patient has OHP, initiate a prior authorization with complete documentation (LDL-C value, statin history, ezetimibe trial, clinical diagnosis) to minimize denial risk.
3. If uninsured and income is below 600% FPL, apply for Praluent MySupport free-drug program before any other option.
4. If commercial coverage is denied after appeal and OHP or MySupport is unavailable, obtain a 503A compounded prescription with documented clinical rationale and prescribe from a licensed Oregon compounding pharmacy.

Can You Get Praluent Through Telehealth in Oregon?

Telehealth prescribing of alirocumab is legal and widely available in Oregon. Oregon law permits controlled and non-controlled prescription drugs to be prescribed via synchronous audio-video telehealth encounters without a prior in-person visit, provided an appropriate prescriber-patient relationship is established. [13]

Alirocumab is not a controlled substance, so the prescribing threshold is lower than it is for, say, buprenorphine or stimulants. A licensed Oregon physician, nurse practitioner, or physician assistant can evaluate a patient's LDL-C history, review statin and ezetimibe trial documentation, confirm the relevant diagnosis (HeFH or established ASCVD), and write an alirocumab prescription entirely via telehealth. [13]

Practical requirements for a telehealth alirocumab visit in Oregon include access to the patient's recent lab work (typically a fasting lipid panel from within the past 12 months), documentation of current statin and any other lipid-lowering medications, and a clear record of prior cardiovascular events or FH diagnosis if applicable. Patients should have labs uploaded or faxed to the telehealth platform before the visit to avoid delays.

The ACC and AHA jointly published a 2020 statement supporting telehealth for cardiovascular disease management, noting that "telehealth can extend the reach of guideline-directed medical therapy to patients who face geographic or financial barriers to in-person specialist care." [14] Oregon's rural geography, particularly in eastern Oregon counties with limited cardiology access, makes this pathway especially relevant.

HealthRX clinicians complete a thorough chart review and lipid history assessment at each initial telehealth visit before prescribing alirocumab. Repeat LDL-C testing at 4 to 12 weeks after starting therapy is standard practice to confirm response, with a target LDL-C below 70 mg/dL for ASCVD patients and below 100 mg/dL for primary prevention cases. [3]

What Are the Clinical Expectations Once Alirocumab Is Started?

Alirocumab typically lowers LDL-C by 45 to 60% from baseline within 4 weeks, with maximum effect at 8 to 12 weeks. For patients at very high cardiovascular risk, that reduction can be the difference between a target LDL-C achieved and one that remains dangerously elevated.

The ODYSSEY MONO trial (N=103) showed a 47.2% mean reduction in LDL-C from baseline at 24 weeks for alirocumab 75 mg every two weeks versus 15.6% for ezetimibe (P<0.001). [15] The dose can be uptitrated to 150 mg every two weeks at the 8-week mark if LDL-C response is insufficient, a decision usually based on a repeat fasting lipid panel. [1]

Safety data from the ODYSSEY OUTCOMES trial (N=18,924, median follow-up 2.8 years) showed no significant increase in serious adverse events compared with placebo. [2] Injection-site reactions occurred in 3.8% of alirocumab-treated patients versus 2.1% of placebo patients. Neurocognitive events, which were a theoretical concern when PCSK9 inhibition was first studied, were not statistically elevated in the alirocumab group compared with placebo in that trial. [2]

Patients on maximally tolerated statin therapy who add alirocumab can expect a combined LDL-C reduction of 65 to 75% from their pre-statin baseline, based on pooled ODYSSEY program data. [16] For a patient with baseline LDL-C of 180 mg/dL who achieves only 100 mg/dL on high-intensity statin plus ezetimibe, alirocumab could plausibly bring that figure to 50 to 60 mg/dL, well below the ACC/AHA 2018 guideline target of 70 mg/dL for very high-risk ASCVD patients. [3]

The drug is administered via a prefilled autoinjector pen. Injection sites include the abdomen, upper thigh, or upper arm. Patients typically self-administer after a brief training session. Storage requires refrigeration (36 to 46 degrees Fahrenheit), though the pen can be kept at room temperature for up to 30 days before use. Pens must not be frozen or shaken. [1]

How Does Praluent Compare With Repatha (Evolocumab) on Cost in Oregon?

Evolocumab (Repatha) carries a similar list price of approximately $573 per month at retail in Oregon, making the two drugs effectively equivalent on cash-pay cost. The choice between them for most Oregon patients comes down to formulary placement, not price.

Both alirocumab and evolocumab block PCSK9 and produce comparable LDL-C reductions in head-to-head analyses. The FOURIER trial of evolocumab (N=27,564) showed a 59% reduction in LDL-C and a 15% relative risk reduction in the primary composite cardiovascular endpoint, closely paralleling the ODYSSEY OUTCOMES results for alirocumab. [17] Neither drug has a demonstrated superiority over the other on cardiovascular outcomes in direct comparative trials.

For Oregon OHP patients, the formulary tier assigned by a patient's CCO may favor one drug over the other. Patients who fail prior authorization for one should consider whether the other PCSK9 inhibitor carries a more accessible PA pathway under their specific CCO. Prescribers can request a formulary exception or appeal using the same ACC guideline language cited above. [5]

Inclisiran (Leqvio), a small interfering RNA PCSK9 inhibitor dosed twice yearly, received FDA approval in December 2021 and offers a different dosing schedule that some patients find more convenient. [18] Its list price is comparable to alirocumab and evolocumab, and Oregon Medicaid coverage follows a similar prior authorization process. Inclisiran is not yet available as a compounded product through 503A pharmacies.